MAPS is currently sponsoring MAPP2, the second of two Phase 3 trials to support FDA approval of this breakthrough-designated therapy.
In their first Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic scores two months after their third session of MDMA-assisted therapy, compared to 60% of placebo participants.
Additionally, 67% of participants in the MDMA group compared to 32% of participants in the placebo group no longer met the criteria for PTSD remission two months after the sessions.
This article, published in maps.org explains how MDMA-assisted therapy works, and includes several studies on the subject.
